Lilopristone(CAS: 97747-88-1)

Lilopristone (CAS: 97747-88-1) falls under the regulatory scope of the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) and is subject to the European Union’s Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) regulation. Additionally, it is regulated by the U.S. Environmental Protection Agency (EPA) and the Food and Drug Administration (FDA) for its intended use. Manufacturers and importers must ensure compliance with specific guidelines for classification, labeling, and documentation.

Several alternatives to lilopristone (CAS: 97747-88-1) exist in synthesis, including analogs such as ciprofloxacin and isomers like norfloxacin. Substitute reagents like fluoroquinolones and other similar compounds are often used as alternatives. These alternatives offer similar pharmacological properties and can be employed based on specific research or industrial requirements.

The market and research trends for lilopristone (CAS: 97747-88-1) are focused on its potential applications in managing certain medical conditions. Research is ongoing to explore its efficacy and safety in clinical trials. Market trends indicate increasing interest due to its unique pharmacological profile, though its commercialization is still in the nascent stages. Continued investigation into its mechanism of action and potential therapeutic uses will shape future market dynamics.

Waste containing lilopristone (CAS: 97747-88-1) should be managed according to waste handling guidelines. It should be collected in appropriate containers, labeled with the chemical name and CAS number, and stored in a secure area. Professional waste disposal services should be used for its incineration or other suitable methods to ensure environmental safety. Environmental protection measures, such as neutralization and proper containment, are critical to prevent any potential environmental impact.